A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib
- Type de publi. : Article dans une revue
- Date de publi. : 01/07/2007
-
Auteurs :
Thibault de La Motte RougeLorenzo GalluzziKen OlaussenYael ZermatiEzgi TasdemirThomas RobertHugues RipocheVladimir LazarPhilippe DessenFrancis HarperGerard PierronGuillaume PinnaNatalia AraujoAnnick Harel-BelanJean-Pierre ArmandTai Wai WongJean Charles SoriaGuido Kroemer
-
Organismes :
Institut Gustave Roussy
Apoptose, cancer et immunité
Institut Gustave Roussy
Apoptose, cancer et immunité
Institut Gustave Roussy
Apoptose, cancer et immunité
Apoptose, cancer et immunité
Institut Gustave Roussy
Institut Gustave Roussy
Apoptose, cancer et immunité
Institut Gustave Roussy
Bases fondamentales et stratégies nouvelles en cancérologie
Institut Gustave Roussy
Génomes et cancer
Institut Gustave Roussy
Institut Gustave Roussy
Génomes et cancer
Réplication de l’ADN et Ultrastructure du Noyau [Villejuif]
Réplication de l’ADN et Ultrastructure du Noyau [Villejuif]
Laboratoire Epigenetique et Cancer
Laboratoire Epigenetique et Cancer
Laboratoire Epigenetique et Cancer
Institut Gustave Roussy
Bristol-Myers Squibb [Princeton]
Institut Gustave Roussy
Institut Gustave Roussy
Apoptose, cancer et immunité
- Publié dans Cancer Research le 29/10/2020
Résumé : Abstract Non–small cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) responds to EGFR tyrosine kinase inhibitors such as erlotinib. However, secondary somatic EGFR mutations (e.g., T790M) confer resistance to erlotinib. BMS-690514, a novel panHER/vascular endothelial growth factor receptor (VEGFR) inhibitor described here, exerted antiproliferative and proapoptotic effects on NSCLC cell lines, with prominent efficacy on H1975 cells expressing the T790M mutation. In this model, BMS-690514 induced a G1 cell cycle arrest, as well as ultrastructural hallmarks of apoptosis, mitochondrial release of cytochrome c, and activation of caspases involved in the intrinsic (e.g., caspase-2, caspase-3, caspase-7, and caspase-9), but not in the extrinsic (e.g., caspase-8), pathway. Caspase inhibition conferred partial protection against BMS-690514 cytotoxicity, pointing to the involvement of both caspase-dependent and caspase-independent effector mechanisms. Transcriptome analyses revealed the up-regulation of proapoptotic (e.g., Bim, Puma) and cell cycle inhibitory (e.g., p27Kip1, p57Kip2) factors, as well as the down-regulation of antiapoptotic (e.g., Mcl1), heat shock (e.g., HSP40, HSP70, HSP90), and cell cycle promoting [e.g., cyclins B1, D1, and D3; cyclin-dependent kinase 1 (CDK1); MCM family proteins; proliferating cell nuclear antigen (PCNA)] proteins. BMS-690514–induced death of H1975 cells was modified in a unique fashion by a panel of small interfering RNAs targeting apoptosis modulators. Down-regulation of components of the nuclear factor-κB survival pathway (e.g., p65, Nemo/IKKγ, TAB2) sensitized cells to BMS-690514, whereas knockdown of proapoptotic factors (e.g., Puma, Bax, Bak, caspase-2, etc.) and DNA damage–related proteins (e.g., ERCC1, hTERT) exerted cytoprotective effects. BMS-690514 is a new pan-HER/VEGFR inhibitor that may become an alternative to erlotinib for the treatment of NSCLC. [Cancer Res 2007;67(13):6253–62]
Source